Croma-Pharma Secures FDA Approval for Obagi saypha® ChIQ™ to Expand Facial Aesthetic Treatment Options in the U.S.
Croma-Pharma has reached another significant milestone in its global growth strategy with the U.S. Food and Drug Administration (FDA) approving Obagi saypha® ChIQ™, an injectable hyaluronic acid gel designed for cheek augmentation and the correction of midface contour deficiencies in adults aged 21 years and older. The approval represents another major achievement for the Austria-based medical aesthetics company as it continues expanding its portfolio of minimally invasive injectable treatments in the United States.
The newly approved product will be marketed in the U.S. by Obagi Medical, a Waldencast company, under the Obagi saypha® brand. The approval follows the successful FDA clearance of Obagi saypha® MagIQ™ in September 2025, making ChIQ™ the second FDA-approved product from Croma-Pharma’s injectable aesthetics portfolio available in the U.S. market.
The latest regulatory milestone highlights the company’s commitment to strengthening its presence in one of the world’s largest and fastest-growing medical aesthetics markets while providing healthcare professionals with additional treatment options to address increasing patient demand for minimally invasive cosmetic procedures.
Expanding Treatment Options for Facial Rejuvenation
Obagi saypha® ChIQ™ is specifically indicated for cheek augmentation and the correction of midface contour deficiencies, helping practitioners restore facial volume and improve facial harmony using hyaluronic acid-based dermal filler technology.
The approval provides physicians, dermatologists, plastic surgeons, and other qualified aesthetic practitioners with an additional injectable solution designed to create natural-looking facial enhancement while maintaining predictable treatment outcomes.
Facial aging commonly results in volume loss in the cheeks and midface due to reductions in collagen, fat, and naturally occurring hyaluronic acid. This loss of volume can contribute to sagging skin, deeper facial folds, and changes in overall facial proportions. Hyaluronic acid fillers have become one of the most widely used treatment options for restoring facial volume because they provide immediate results without the need for surgery.
The FDA approval of ChIQ™ expands the range of available treatment options for patients seeking minimally invasive procedures that require limited recovery time while delivering aesthetic improvements.
Growing Demand for Minimally Invasive Aesthetic Procedures
The approval comes as global demand for non-surgical aesthetic treatments continues to rise. Increasing numbers of consumers are choosing injectable procedures over traditional surgical interventions because of shorter treatment times, reduced downtime, and natural-looking outcomes.
Healthcare professionals are also seeking products that combine proven clinical performance with consistent manufacturing quality and reliable safety profiles.
By adding Obagi saypha® ChIQ™ to its U.S. portfolio, Croma-Pharma further positions itself to address these evolving market trends while supporting physicians with scientifically developed injectable products.
The approval reflects broader industry growth in facial rejuvenation procedures, where hyaluronic acid fillers remain among the most commonly performed aesthetic treatments worldwide.
Building the saypha® Portfolio in the United States
The FDA authorization represents another important step in expanding Croma-Pharma’s saypha® product family within the United States.
The launch follows the earlier approval of Obagi saypha® MagIQ™, creating a broader range of injectable products that address different facial aesthetic needs.
By steadily expanding its FDA-approved portfolio, the company aims to establish a stronger position in the highly competitive U.S. medical aesthetics sector while supporting healthcare professionals with complementary treatment solutions.
According to Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH, the approval demonstrates the company’s continued investment in scientific research and innovation.
Prinz stated that ChIQ™ represents the second FDA-approved product in the company’s portfolio and reinforces Croma-Pharma’s long-standing commitment to scientific excellence, high manufacturing standards, and continuous innovation within aesthetic medicine.
He emphasized that expanding the availability of the saypha® portfolio in the United States remains an important strategic objective for the company.
Nearly Five Decades of Scientific and Manufacturing Expertise
Croma-Pharma brings decades of experience to the medical aesthetics industry.
Founded nearly fifty years ago, the company has established expertise across multiple medical applications by combining scientific research with advanced manufacturing capabilities.
Originally building its reputation through ophthalmology, Croma later expanded into hyaluronic acid technologies and minimally invasive medical treatments, becoming one of Europe’s established manufacturers of injectable aesthetic products.
Its manufacturing facilities in Austria serve as the production center for its injectable portfolio.
Over the years, the company has produced more than 130 million syringes, demonstrating significant manufacturing scale while maintaining quality standards designed to meet international regulatory requirements.
The company’s experience in hyaluronic acid formulation and production has helped support the development of products intended to provide physicians with reliable performance and patients with consistent treatment outcomes.
The FDA approval of ChIQ™ further validates the company’s manufacturing expertise and regulatory capabilities as it expands into additional international markets.
Partnership with Obagi Medical
A key element of the U.S. commercialization strategy is Croma-Pharma’s partnership with Obagi Medical, which is responsible for bringing the approved products to healthcare providers across the United States.
Obagi Medical, a Waldencast company, has built a strong reputation in physician-dispensed skincare and aesthetic solutions, making it a strategic commercial partner for introducing Croma’s injectable products to the U.S. market.
Through this collaboration, healthcare professionals gain access to injectable products that complement Obagi’s existing skincare offerings, creating a more comprehensive aesthetic treatment portfolio.
The partnership enables physicians to combine injectable facial contouring procedures with advanced skincare regimens to support broader facial rejuvenation strategies.
Waldencast Highlights Portfolio Expansion
Michel Brousset, Co-Founder and Chief Executive Officer of Waldencast, described the approval as an important addition to the company’s growing aesthetic offerings.
According to Brousset, Obagi saypha® ChIQ™ expands the company’s integrated aesthetics portfolio by providing practitioners and patients with additional options for achieving comprehensive skin transformation through predictable and measurable treatment outcomes.
He noted that the approval strengthens Waldencast’s ability to address changing patient expectations by delivering science-based aesthetic solutions supported by clinical evidence.
The addition of ChIQ™ further enhances Obagi Medical’s injectable offerings while complementing its established skincare products.
Responding to Evolving Patient Expectations
Modern aesthetic patients increasingly seek treatments that provide subtle enhancements rather than dramatic changes.
Natural-looking facial rejuvenation has become a key objective for both patients and practitioners, driving demand for injectable products capable of restoring youthful facial contours while preserving individual facial characteristics.
Hyaluronic acid fillers continue to play a central role in meeting these expectations because they provide temporary yet effective facial volume restoration using a substance naturally found within the body.
With ChIQ™, practitioners gain another FDA-approved treatment option designed specifically for improving cheek volume and correcting midface contour deficiencies through minimally invasive procedures.
The approval supports broader access to evidence-based treatments while expanding patient choice in facial aesthetics.
Strengthening Croma-Pharma’s U.S. Presence
The FDA approval of Obagi saypha® ChIQ™ represents more than a single product launch—it reinforces Croma-Pharma’s long-term strategy to strengthen its footprint in the United States and expand its global aesthetics business.
By successfully obtaining regulatory approvals for multiple injectable products, the company continues building momentum within one of the industry’s most competitive markets.
The latest authorization also strengthens the ongoing collaboration between Croma-Pharma and Obagi Medical, supporting the introduction of additional science-backed aesthetic solutions to U.S. healthcare professionals.
As demand for minimally invasive cosmetic treatments continues growing worldwide, the approval positions both companies to serve an expanding patient population seeking safe, effective, and natural-looking facial rejuvenation options.
With Obagi saypha® ChIQ™ now approved for commercial use in the United States, Croma-Pharma further advances its mission of combining scientific innovation, manufacturing excellence, and clinical expertise to expand access to modern injectable aesthetic treatments while continuing to grow its internationally recognized saypha® portfolio.
Source Link: https://www.businesswire.com/
